27438230|t|Modern Image-Guided Intensity-Modulated Radiotherapy for Oropharynx Cancer and Severe Late Toxic Effects: Implications for Clinical Trial Design
27438230|a|Late toxic effects are common after definitive radiotherapy and chemoradiotherapy for oropharynx cancer and are considered a significant contributor to decreased quality of life for survivors. The incidence of severe late toxic effects may be reduced by modern narrow-margin image-guided intensity-modulated radiotherapy (IG-IMRT), current supportive care improvements, and the changing epidemiology of oropharynx cancer. Assess the incidence of severe late toxic effects after modern definitive non-operative treatment for oropharynx cancer. For this single-institution retrospective review, 156 patients with stage I-IVB squamous cell carcinoma of the oropharynx treated between April 2009 and February 2015 at a tertiary-referral academic multidisciplinary head and neck practice were recruited. Definitive narrow-margin IG-IMRT to a dose of 66 Gy (to convert milligray to rad, multiply by 0.1) or higher with or without concurrent cisplatin. The primary outcome was the prospectively collected 2- year cumulative incidence of severe late toxic effects (Common Terminology Criteria for Adverse Events grade 3 or higher) occurring 3 months or more after radiotherapy. Toxic effect end points investigated included esophageal stricture requiring dilation, aspiration pneumonia hospitalization, vocal dysfunction, delayed feeding tube insertions, and osteoradionecrosis. Feeding tube dependence at 1 year was also considered a severe late toxic effect. Secondary outcomes collected include physician -reported grade 2 or higher neck fibrosis and xerostomia. The competing risks of recurrence and death were accounted for using the Gray method. One-hundred fifty-six patients (median [range] age, 58 [37-96] years) were identified; 130 patients (83%) were HPV positive. Concurrent cisplatin was delivered in 131 patients (84%) and 5 patients (3%) underwent an adjuvant neck dissection. The median (range) follow-up for survivors was 22 (4-73) months from diagnosis. The projected 2- year locoregional control was 93% (95% CI, 88.4%-97.6%) and overall survival was 88% (95% CI, 82.2%-94.0%). Thirty-eight patients (23%) required a feeding tube during treatment. The cumulative incidence of severe late toxic effects adjusted for competing risks at 2- year posttreatment was 2.3% (95% CI, 0%-5.6%). One patient required free-flap reconstruction for grade 3 osteoradionecrosis at 47 months. At 1 year, 2 patients (1%) experienced grade 2 neck fibrosis and 38 patients (23%) experienced grade 2 xerostomia. These results suggest that severe late toxic effects after modern definitive IG-IMRT, with or without cisplatin, for oropharynx cancer is likely uncommon. The importance of late toxic effect reduction in current and future investigational strategies, including clinical trials, should be considered.
27438230	7	52	Image-Guided Intensity-Modulated Radiotherapy	T061	C1512814
27438230	57	74	Oropharynx Cancer	T191	C0153382
27438230	86	104	Late Toxic Effects	T046	C0160814
27438230	123	144	Clinical Trial Design	T201	C1507647
27438230	145	163	Late toxic effects	T046	C0160814
27438230	192	204	radiotherapy	T061	C1522449
27438230	209	226	chemoradiotherapy	T061	C0436307
27438230	231	248	oropharynx cancer	T191	C0153382
27438230	307	322	quality of life	T078	C0034380
27438230	327	336	survivors	T101	C0206194
27438230	362	380	late toxic effects	T046	C0160814
27438230	406	419	narrow-margin	T201	C3641165
27438230	420	465	image-guided intensity-modulated radiotherapy	T061	C1512814
27438230	467	474	IG-IMRT	T061	C1512814
27438230	532	544	epidemiology	T091	C0014507
27438230	548	565	oropharynx cancer	T191	C0153382
27438230	598	616	late toxic effects	T046	C0160814
27438230	641	664	non-operative treatment	T061	C0087111
27438230	669	686	oropharynx cancer	T191	C0153382
27438230	742	750	patients	T101	C0030705
27438230	768	809	squamous cell carcinoma of the oropharynx	T191	C0280313
27438230	810	817	treated	T061	C0087111
27438230	860	927	tertiary-referral academic multidisciplinary head and neck practice	T073,T093	C0587437
27438230	955	968	narrow-margin	T201	C3641165
27438230	969	976	IG-IMRT	T061	C1512814
27438230	982	986	dose	T081	C0178602
27438230	1080	1089	cisplatin	T121,T197	C0008838
27438230	1103	1110	outcome	T169	C1274040
27438230	1146	1150	year	T079	C0439234
27438230	1151	1171	cumulative incidence	T081	C0021149
27438230	1182	1200	late toxic effects	T046	C0160814
27438230	1202	1248	Common Terminology Criteria for Adverse Events	T170	C3888020
27438230	1249	1256	grade 3	T033	C1519275
27438230	1280	1286	months	T079	C0439231
27438230	1301	1313	radiotherapy	T061	C1522449
27438230	1315	1327	Toxic effect	T037	C0600688
27438230	1361	1381	esophageal stricture	T047,T190	C0014866
27438230	1392	1400	dilation	T061	C1322279
27438230	1402	1422	aspiration pneumonia	T047	C0032290
27438230	1423	1438	hospitalization	T058	C0019993
27438230	1440	1457	vocal dysfunction	T184	C1657467
27438230	1467	1490	feeding tube insertions	T061	C0021931
27438230	1496	1514	osteoradionecrosis	T046	C0029461
27438230	1516	1528	Feeding tube	T074	C2945625
27438230	1545	1549	year	T079	C0439234
27438230	1579	1596	late toxic effect	T046	C0160814
27438230	1598	1607	Secondary	T081	C0205436
27438230	1608	1616	outcomes	T169	C1274040
27438230	1635	1644	physician	T097	C0031831
27438230	1655	1662	grade 2	T080	C1522446
27438230	1673	1677	neck	T029	C0027530
27438230	1678	1686	fibrosis	T046	C0016059
27438230	1691	1701	xerostomia	T033	C0043352
27438230	1717	1722	risks	T058	C0035649
27438230	1741	1746	death	T040	C0011065
27438230	1776	1787	Gray method	T170	C0025663
27438230	1811	1819	patients	T101	C0030705
27438230	1836	1839	age	T032	C0001779
27438230	1852	1857	years	T079	C0439234
27438230	1880	1888	patients	T101	C0030705
27438230	1900	1912	HPV positive	T034	C4288937
27438230	1925	1934	cisplatin	T121,T197	C0008838
27438230	1956	1964	patients	T101	C0030705
27438230	1977	1985	patients	T101	C0030705
27438230	2013	2028	neck dissection	T061	C0398395
27438230	2063	2072	survivors	T101	C0206194
27438230	2087	2093	months	T079	C0439231
27438230	2099	2108	diagnosis	T033	C0011900
27438230	2127	2131	year	T079	C0439234
27438230	2132	2144	locoregional	T082	C1947913
27438230	2145	2152	control	T080	C0243148
27438230	2166	2168	CI	T081	C0021149
27438230	2187	2203	overall survival	T081	C4086681
27438230	2217	2219	CI	T081	C0021149
27438230	2248	2256	patients	T101	C0030705
27438230	2274	2286	feeding tube	T074	C2945625
27438230	2294	2303	treatment	T061	C0087111
27438230	2309	2329	cumulative incidence	T081	C0021149
27438230	2340	2358	late toxic effects	T046	C0160814
27438230	2382	2387	risks	T058	C0035649
27438230	2394	2398	year	T079	C0439234
27438230	2399	2412	posttreatment	T079	C2709088
27438230	2427	2429	CI	T081	C0021149
27438230	2445	2452	patient	T101	C0030705
27438230	2462	2486	free-flap reconstruction	T061	C0411582
27438230	2499	2517	osteoradionecrosis	T046	C0029461
27438230	2524	2530	months	T079	C0439231
27438230	2537	2541	year	T079	C0439234
27438230	2545	2553	patients	T101	C0030705
27438230	2571	2578	grade 2	T080	C1522446
27438230	2579	2583	neck	T029	C0027530
27438230	2584	2592	fibrosis	T046	C0016059
27438230	2600	2608	patients	T101	C0030705
27438230	2627	2645	grade 2 xerostomia	T033	C1560329
27438230	2681	2699	late toxic effects	T046	C0160814
27438230	2724	2731	IG-IMRT	T061	C1512814
27438230	2749	2758	cisplatin	T121,T197	C0008838
27438230	2764	2781	oropharynx cancer	T191	C0153382
27438230	2820	2837	late toxic effect	T046	C0160814
27438230	2908	2923	clinical trials	T062	C0008976